BSF Enterprise Plc (LON:BSFA) investors were spurred into action on Monday morning in response to a promising commercial progress update on its subsidiary 3D Bio Tissues’ flagship City-Mix product.
A number of commercial opportunities have arisen for 3D Bio Tissues since designing and implementing its go-to-market plan for City-Mix in the last quarter of 2022, and notably, the group has secured its first agreement after completing a successful evaluation of City-Mix.
In order to be ready to serve these opportunities the company has now more than doubled its lab production space to 2,400 square feet.
BSF shares were seen at 16.55p with a market capitalisation of £14.2mln as of 10.15am, March 6.